News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK Rejects Roche (RHHBY)'s Avastin in Advanced Breast Cancer


7/6/2012 6:32:35 AM

Roche Holding AG's cancer drug Avastin has been rejected by Britain's healthcare cost agency as a first-line treatment for advanced breast cancer, the latest in a series of setbacks for this medicine. The National Institute for Health and Clinical Excellence (NICE) said on Friday that although Avastin, when used in combination with the chemotherapy drug Xeloda, could delay cancer from progressing longer than chemotherapy alone, it did not appear to help breast cancer patients live longer overall. There were also question marks over whether or not Avastin, known generically as bevacizumab, could improve a patient's quality of life, according to NICE's Ch ief Executive A ndrew Dillon.

Read at Reuters
Read at InPharm.com
Read at Telegraph
Read at News Release


comments powered by Disqus
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES